The global alpha-1
antitrypsin deficiency treatment market is characterized by a large
number of regional and global players, making its vendor landscape,
a fragmented one, states Transparency Market Research (TMR) in its
latest report. Leading companies within the market are: Teva
Pharmaceutical Industries Ltd., Pfizer Inc., Baxter, Boehringer
Ingelheim GmbH, Shire plc, Kamada Ltd., AstraZeneca, LFB
Biomedicaments S.A., Grifols S.A., GlaxoSmithKline Plc., and CSL
Behring LLC.
Request for
Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13214
It is anticipated
that many new biotechnology companies will venture into the alpha-1
antitrypsin deficiency treatment market, and work towards the
development of personalized medicines for genetically inherited
disorders. They are also likely to invest extensively in R&D for
coming up with novel treatment processes and for the development of
stem cell based therapeutics.
According to TMR,
the global alpha-1 antitrypsin deficiency treatment market will
expand at a more than healthy10.3% CAGR from 2017 to 2025, and be
valued at US$2,908.1 mn by the end of 2025. On the basis of treatment
type, the augmentation therapy segment has been leading, with the
bronchodilator treatment segment trailing in the second position.
On the basis of end
user, the hospital segment emerged as the leading one, while the
parenteral segment has emerged as the most popular route of
administration. On the basis of geography, North America has been
leading in the alpha-1 antitrypsin deficiency treatment market, on
account of the rising diagnosis rate, increasing prevalence of
alpha-1 antitrypsin deficiency, and high healthcare expenditure.
Request Report
Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13214
Market Players to
Benefit from Investing in Emerging Nations
The recent
advancements in the diagnosis of apha-1 antitrypsin deficiency, has
boded well for the growth of the apha-1 antitrypsin deficiency
treatment market and with the rising prevalence of respiratory
diseases, it is slated that this market will continue to witness
growth. As per a TMR analyst, “the high unmet medical needs in the
developing nations as well as improvement in the healthcare
facilities in these nations offers market players, lucrative
opportunities to grow. Moreover, the support from government will
also work in their favour. As per the Forum of International
Respiratory Societies (FIRS), COPD is likely to be the fourth leading
cause of death by 2030 and every year over 235 mn people across the
globe are detected with asthma.
Alpha-1
antitrypsin Supply Falling Short
Technological
advancements have resulted in safer production and purification
processes of alpha-1 antitrypsin making them free from virus and
other contaminants such as protein. This in turn has increased the
preference for plasma derived alpha-1 antitrypsin and IVIG. On the
downside however, the global alpha-1 antitrypsin deficiency treatment
market is challenged by the high cost of drugs and shortage of
alpha-1 antitrypsin supply. The market is also restricted by limited
plasma fractionation capacity and stringent regulations.
Enquiry for
discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=13214
About Us
Transparency Market
Research is a next-generation market intelligence provider, offering
fact-based solutions to business leaders, consultants, and strategy
professionals.
Our reports are
single-point solutions for businesses to grow, evolve, and mature.
Our real-time data collection methods along with ability to track
more than one million high growth niche products are aligned with
your aims. The detailed and proprietary statistical models used by
our analysts offer insights for making right decision in the shortest
span of time. For organizations that require specific but
comprehensive information we offer customized solutions through adhoc
reports. These requests are delivered with the perfect combination of
right sense of fact-oriented problem solving methodologies and
leveraging existing data repositories.
TMR believes that
unison of solutions for clients-specific problems with right
methodology of research is the key to help enterprises reach right
decision.
US Office
Contact
90 State Street,
Suite 700
Albany, NY 12207
Tel:
+1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment